Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $23.63, for a total value of $472,600.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at approximately $1,023,131.74. This trade represents a 31.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kevin Patrick Danahy also recently made the following trade(s):

• On Friday, February 13th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Trading Up 7.6%

Shares of PLSE opened at $25.46 on Thursday. Pulse Biosciences, Inc has a twelve month low of $12.56 and a twelve month high of $26.30. The firm has a market capitalization of $1.73 billion, a P/E ratio of -22.53 and a beta of 1.77. The firm’s 50-day moving average is $15.98 and its two-hundred day moving average is $15.97.

Analyst Ratings Changes

PLSE has been the topic of a number of research analyst reports. Mizuho set a $30.00 target price on Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $26.00.

Institutional Investors Weigh In On Pulse Biosciences

A number of large investors have recently bought and sold shares of PLSE. BNP Paribas Financial Markets raised its holdings in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the last quarter. KLP Kapitalforvaltning AS lifted its holdings in Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after purchasing an additional 3,400 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after purchasing an additional 5,748 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.